CONNECT WITH US
HealthTech

HealthTech

Drug discovery by scientists joins world's largest trial of Parkinson's treatments

Medical Xpress logo

Published on

Add as a preferred source on Google
Drug discovery by scientists joins world's largest trial of Parkinson's treatments

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A liver drug could be used to slow down the progression of Parkinson's disease as it joins the world's largest trial of treatments for the condition.

This comes after researchers at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust discovered that ursodeoxycholic acid (UDCA) has considerable promise to improve the function of mitochondria, known as the cell's power plants, in Parkinson's disease and, by doing so, slow the progression of this currently relentlessly progressive disease.

UDCA was identified as a potential new avenue for treatment of Parkinson's following groundbreaking University of Sheffield–led research that screened an entire drug library in tissue samples from Parkinson's patients for the first time.

It is now the third of a new wave of treatments with disease-modifying potential to be tested in parallel against a placebo in the Edmond J Safra Accelerating Clinical Trials in Parkinson's Disease (EJS ACT-PD) trial.

The loss of mitochondrial function in dopamine-producing nerve cells in the movement-controlling area of the brain is believed to play an important role in the progression of Parkinson's. By protecting these nerve cells from cellular malfunction, researchers believe UDCA can play a key role in slowing Parkinson's progression.

The inclusion of the UDCA drug in the innovative multidrug EJS ACT-PD trial marks an important milestone for the platform, which aims to speed up the search for effective treatments for Parkinson's by testing more drugs faster and more efficiently than ever before.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.